General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YDJWB
ADC Name
LC-V205C-1a
Synonyms
LC-V205C-1a
   Click to Show/Hide
Organization
National Institute of Health Sciences
Drug Status
Investigative
Drug-to-Antibody Ratio
1.8-2
Structure
Antibody Name
Trastuzumab
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Undisclosed
Conjugate Type
Site specific conjugation at LC-K149C.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
> 3
nM
CVCL_0033
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) > 3 nM Positive HER2 expression (HER2+++/++)
Method Description
SK-BR-3 cells (a HER2-positive cell line) were seeded at 2000 cells/well in a 96-well plate and incubated overnight at 37°C in a humidified atmosphere containing 5% CO2. The cells were treated with serially diluted homogeneous ADCs and incubated for 4 days at 37°C in a humidified atmosphere containing 5% CO2. The cytotoxicity was evaluated using the Cell Counting Kit SF (Nacalai Tesque). Each dose-response curve was fitted by 4-parameter logistic model with same upper/lower asymptotes using GraphPad prism 7 software, and calculated IC50 of homogeneous ADCs

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
References
Ref 1 Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity